Howe & Rusling’s Evogene EVGN Stock Holding History

Howe & Rusling’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-90	Closed	-$1K	–	1091
2022 Q1	$1K	Hold	90	–	–	﹤0.01%	926
2021 Q4	$1K	Hold	90	–	–	﹤0.01%	925
2021 Q3	$2K	Buy	+90	New	+$2.63K	﹤0.01%	838

Other funds holding EVGN

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EVC

Eidelman Virant Capital Saint Louis, Missouri $136M AUM 15.11% 1-Year Est. Return

VIA

Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAG

Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return

Howe & Rusling's EVGN Position: Q2 2022 in Review

Howe & Rusling sold out of Evogene (EVGN) in Q2 2022, closing a stake of 90 shares — an estimated $1K sold.

Howe & Rusling first reported a position in EVGN in Q3 2021 and held it in 3 quarters. The position peaked at $2K in Q3 2021. 29 funds tracked by Wall St. Rank hold EVGN as of Q2 2022.

Howe & Rusling reported no remaining Evogene position as of Q2 2022 after selling out during the quarter.
Howe & Rusling sold 90 Evogene shares in Q2 2022, an estimated $1K.
Howe & Rusling first reported a position in Evogene in Q3 2021 and held it in 3 quarters.
Howe & Rusling's Evogene position peaked at $2K in Q3 2021.
29 funds tracked by Wall St. Rank held Evogene as of Q2 2022.

Based on Howe & Rusling's 13F filing for Q2 2022, filed 15 Aug 2022.